| Q46123564 | A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality. |
| Q40287559 | A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children |
| Q36075481 | A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper |
| Q52372446 | A review on stem cell therapy for multiple sclerosis: special focus on human embryonic stem cells. |
| Q38711546 | ABO blood group mismatched hematopoietic stem cell transplantation |
| Q42271011 | Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry |
| Q37788415 | Advances in umbilical cord transplantation: the role of thymoglobulin/ATG in cord blood transplantation |
| Q35446852 | Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after |
| Q34141361 | Allogeneic hematopoietic stem cell transplantation as the first-line treatment option in a patient with severe aplastic anemia without a matched related donor: A case report |
| Q57267894 | Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica |
| Q37842488 | Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations |
| Q42852351 | Allogeneic stem cell transplantation for adult acute lymphoblastic leukemia: when and how. |
| Q24200183 | Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma |
| Q24203887 | Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma |
| Q44300500 | Application of five prognostic survival scores to primary myelofibrosis in 62 Brazilian patients. |
| Q38248359 | Autologous hematopoietic cell transplantation: an update for clinicians |
| Q38406849 | Bone mineral density is close to normal for age in long-term lymphoma survivors treated with high-dose therapy with autologous stem cell transplantation |
| Q39233323 | Cell Therapy for Multiple Sclerosis |
| Q34421182 | Chronic kidney disease after hematopoietic stem cell transplantation |
| Q54085734 | Clinical relevance of galectin-1 in hematologic malignancies treated with non-myeloablative hemopoietic stem cell transplantation. |
| Q42145853 | Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation |
| Q34348102 | Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia |
| Q34620456 | Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis |
| Q52960643 | Comparison of the cryoprotective solutions based on human albumin vs. autologous plasma: its effect on cell recovery, clonogenic potential of peripheral blood hematopoietic progenitor cells and engraftment after autologous transplantation. |
| Q53167841 | Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma. |
| Q88737362 | Continuous Mononuclear Cell Collection (cMNC) protocol impact on hematopoietic stem cell collections in donors with negative collection predictors |
| Q45876267 | Cord blood hematopoietic stem cell transplantation in an adolescent with haemophilia |
| Q45332228 | Cord blood stem cell banking: a snapshot of the Italian situation |
| Q45336903 | Cryopreserved stem cell products containing dimethyl sulfoxide lead to activation of the coagulation system without any impact on engraftment. |
| Q38209433 | Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective. |
| Q37904673 | Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. |
| Q47914097 | Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma. |
| Q27024456 | Current translational and clinical practices in hematopoietic cell and gene therapy |
| Q38237573 | Development of coverage with evidence development for medical technologies in Switzerland from 1996 to 2012. |
| Q45888274 | Donor body mass index is an important factor that affects peripheral blood progenitor cell yield in healthy donors after mobilization with granulocyte-colony-stimulating factor |
| Q58668376 | Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations |
| Q87428770 | Efficient purification of CD4+ lymphocytes from peripheral blood progenitor cell products using affinity bead acoustophoresis |
| Q43524297 | Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients. |
| Q88375312 | Epidemiologic Profile of Patients Transplanted With Hematopoietic Stem Cells in a Reference Service in the State of Rio Grande do Norte, Brazil |
| Q34194325 | European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization. |
| Q56897007 | European survey on clinical use of cord blood for hematopoietic and non-hematopoietic indications |
| Q88814971 | Evaluation of Lymphoma Patients Receiving High-Dose Therapy and Autologous Stem Cell Transplantation: Experience of a Single Center |
| Q26740624 | Extracoporeal photopheresis treatment of acute graft-versus-host disease following allogeneic haematopoietic stem cell transplantation |
| Q33889151 | First-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia |
| Q47957199 | Frequent and long-term follow-up of health-related quality of life following allogeneic haematopoietic stem cell transplantation |
| Q42660383 | Fully automated, clinical-grade bone marrow processing: a single-centre experience |
| Q38785195 | Granulocyte colony-stimulating factor impairs CD8(+) T cell functionality by interfering with central activation elements. |
| Q86047180 | HLA antigenic and haplotype frequencies estimated in hematopoietic progenitor cell donors from Argentina |
| Q85888060 | HLA disparity is not crucial for the survival rate and severity of chronic health conditions in adult recipients following family donor hematopoietic stem cell transplantation |
| Q36020897 | Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation |
| Q53137621 | Haploidentical stem cell transplantation for children with high-risk leukemia. |
| Q30636005 | Health technology assessment in Switzerland: a descriptive analysis of "Coverage with Evidence Development" decisions from 1996 to 2013. |
| Q28088687 | Hematopoetic stem cell transplantation in children |
| Q35288778 | Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. |
| Q30616418 | Hematopoietic SCT in Europe: data and trends in 2011. |
| Q33733022 | Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation |
| Q38690071 | Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report |
| Q33855687 | Hematopoietic Stem Cell Transplantation in an Infant with Immunodeficiency, Centromeric Instability, and Facial Anomaly Syndrome. |
| Q38771080 | Hematopoietic progenitor cell mobilization for autologous transplantation - a literature review |
| Q37703126 | Hematopoietic stem cell transplantation activity and trends at a pediatric transplantation center in Turkey during 1998-2008. |
| Q36974379 | Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. |
| Q38978669 | How do we mobilize and collect autologous peripheral blood stem cells? |
| Q37914921 | How we mobilize haemopoietic stem cells. |
| Q28280748 | Human leukocyte antigen profiles of latin american populations: differential admixture and its potential impact on hematopoietic stem cell transplantation |
| Q36666422 | Immunological applications of stem cells in type 1 diabetes |
| Q40208242 | Impact of a change in antibacterial prophylaxis on bacteremia and hospitalization rates following outpatient autologous peripheral blood stem cell transplantation for multiple myeloma |
| Q40763299 | Impact of the source of hematopoietic stem cell in unrelated transplants: comparison between 10/10, 9/10-HLA matched donors and cord blood |
| Q35063668 | Impaired functionality of antiviral T cells in G-CSF mobilized stem cell donors: implications for the selection of CTL donor |
| Q46085344 | Implementation of JACIE accreditation results in the establishment of new indicators that unevenly monitor processes contributing to the delivery of hematopoietic SCT. |
| Q86554028 | Important impact of gingival and periodontal conditions on outcomes in SCT recipients |
| Q38955399 | Improving Outcome of Hodgkins Disease with Autologous Hematopoietic Stem Cell Transplantation |
| Q34477411 | Improving the safety of cell therapy with the TK-suicide gene |
| Q64088774 | Incidence, Risk Factors and Prognosis of Acute Kidney Injury Following Hematopoietic Stem Cell Transplant: A Pilot Study |
| Q36974102 | Increase of suicide and accidental death after hematopoietic stem cell transplantation: a cohort study on behalf of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation (EBMT) |
| Q38098957 | Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies |
| Q38387292 | Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. |
| Q91016714 | Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. |
| Q33987059 | Innate protection from graft-versus-host disease |
| Q41134787 | Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation. |
| Q98465694 | Metabolic Pathways in Alloreactive T Cells |
| Q38044776 | Metabolic syndrome in patients with hematological diseases. |
| Q53549083 | Mobilization of hematopoietic progenitor stem cells in allogeneic setting with lenograstim by subcutaneous injection, in daily or twice-daily dosing: a single-center prospective study with historical control. |
| Q37813006 | Molecular Target Therapy in Hematological Malignancy: Front-runners and Prototypes of Small Molecule and Antibody Therapy |
| Q44401016 | Molecular assessment of minimal residual disease in PBSC harvests provides prognostic information in neuroblastoma. |
| Q39674459 | NK cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT. |
| Q37695076 | Nanofiber-expanded human umbilical cord blood-derived CD34(+) cell therapy accelerates cutaneous wound closure in NOD/SCID mice |
| Q40059776 | Nutritional status of allogeneic hematopoietic stem cell transplantation recipients: influencing risk factors and impact on survival |
| Q41750756 | Nutritional status of patients submitted to transplantation of allogeneic hematopoietic stem cells: a retrospective study |
| Q38384271 | One million haemopoietic stem-cell transplants: a retrospective observational study |
| Q50875591 | Outcome of patients activating an unrelated donor search for severe acquired aplastic anemia. |
| Q54509279 | Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). |
| Q37970679 | Pathogenetic, Clinical, and Prognostic Features of Adult t(4;11)(q21;q23)/MLL-AF4 Positive B-Cell Acute Lymphoblastic Leukemia |
| Q55153801 | Patients' Main Concerns About Having a Sibling Stem Cell Donor - A Grounded Theory Study. |
| Q39814453 | Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation |
| Q35658742 | Pediatric hematopoietic stem cell transplantation in China: Data and trends during 1998-2012. |
| Q40737013 | Physical activity and screen-time of childhood haematopoietic stem cell transplant survivors |
| Q51539866 | Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian exp |
| Q49077951 | Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure |
| Q37921284 | Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma |
| Q48249281 | Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation. |
| Q42740137 | Preventing transmission of infectious agents in the pediatric in-patients hematology-oncology setting: what is the role for non-pharmacological prophylaxis? |
| Q44243900 | Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation |
| Q50798708 | Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. |
| Q91272581 | Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres |
| Q39126825 | Real-time Fatigue and Free-Living Physical Activity in Hematopoietic Stem Cell Transplantation Cancer Survivors and Healthy Controls: A Preliminary Examination of the Temporal, Dynamic Relationship |
| Q50922190 | Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. |
| Q48246032 | Regulation of advanced therapy medicinal products will affect the practice of haematopoietic SCT in the near future: a perspective from the EBMT cell-processing committee |
| Q37802649 | Relevance and Clinical Implications of Tumor Cell Mobilization in the Autologous Transplant Setting |
| Q92999520 | Risk Factors for Transplant Outcomes in Children and Adolescents with Non-Malignant Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation |
| Q53254003 | SNP array analysis of leukemic relapse samples after allogeneic hematopoietic stem cell transplantation with a sibling donor identifies meiotic recombination spots and reveals possible correlation with the breakpoints of acquired genetic aberrations |
| Q42699915 | Single step multiple genotyping by MALDI-TOF mass spectrometry, for evaluation of minor histocompatibility antigens in patients submitted to allogeneic stem cell transplantation from HLA-matched related and unrelated donor |
| Q42697968 | Stem cell therapeutics--reality versus hype and hope |
| Q28072227 | T Cell Receptor Excision Circle (TREC) Monitoring after Allogeneic Stem Cell Transplantation; a Predictive Marker for Complications and Clinical Outcome |
| Q38609242 | The Core of Sibling Stem Cell Donation - A Grounded Theory Study |
| Q43754303 | The EBMT activity survey 2008: impact of team size, team density and new trends |
| Q51887666 | The EBMT activity survey 2009: trends over the past 5 years. |
| Q28265604 | The EBMT activity survey: 1990-2010 |
| Q33452872 | The Mannheim Cord Blood Bank: Experiences and Perspectives for the Future |
| Q38243215 | The graft-versus-neuroblastoma effect of allogeneic hematopoietic stem cell transplantation, a review of clinical and experimental evidence and a perspective on mechanisms |
| Q38547042 | The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients |
| Q30316611 | The indications for allogeneic stem cell transplantation in myeloid malignancies |
| Q38206138 | The role of allogeneic stem cell transplantation in Hodgkin's lymphoma |
| Q38031733 | The role of hematopoietic SCT in adult Burkitt lymphoma |
| Q37860915 | The role of the endothelium in the short-term complications of hematopoietic SCT. |
| Q40320232 | Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. |
| Q37979444 | Transforming growth factor-β1 polymorphisms and the outcome of hematopoietic stem cell transplantation |
| Q38105131 | Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review |
| Q45716180 | Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease. |
| Q33786536 | Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. |
| Q36755496 | What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance |